» Articles » PMID: 28863817

Regulation of P2X Purinergic Receptor Signaling by Cholesterol

Overview
Journal Curr Top Membr
Date 2017 Sep 3
PMID 28863817
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

P2X receptors are cation-selective channels that are activated by the binding of extracellular ATP. They have a high permeability to Ca, Na, and K and are expressed widely throughout the nervous, immune, cardiovascular, skeletal, gastrointestinal, respiratory, and endocrine systems. Seven mammalian subtypes of P2X receptor subunits have been identified, P2X1-7, and those that function as homotrimeric receptors (P2X1, 2, 3, 4, and 7) are targeted to lipid rafts, although they show limited resistance to solubilization by Triton X-100. Recent crystal structures of P2X3 and P2X4 receptors have provided considerable high-resolution information about the architecture of this family of receptors and yet the molecular details of how they are regulated by cholesterol are unknown. Currents mediated by the P2X1-4 receptors are either inhibited or relatively insensitive to cholesterol depletion, but there is no clear evidence to support the direct binding of cholesterol to these receptors. In contrast, the activity of the low-affinity, proinflammatory P2X7 receptor is potentiated by cholesterol depletion and regions within the proximal C-terminus play an important role in coupling changes in cholesterol to the gating of the pore. Based upon our understanding of the lipid signaling events that are triggered downstream of P2X7 receptor activation, a change in the levels of cholesterol may contribute to the sensitization of receptor currents and the dilation of the pore that occurs following prolonged, high-level stimulation. This chapter focuses on the regulation of P2X7 receptor signaling by cholesterol and our current understanding of the mechanisms that underlie this.

Citing Articles

Supramolecular polyrotaxane-based nano-theranostics enable cancer-cell stiffening for enhanced T-cell-mediated anticancer immunotherapy.

Luo H, Lv J, Wen P, Zhang S, Ma W, Yang Z Nat Commun. 2025; 16(1):2331.

PMID: 40057488 PMC: 11890869. DOI: 10.1038/s41467-025-57718-5.


Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism.

Al-Aqtash R, Collier D Channels (Austin). 2024; 18(1):2355150.

PMID: 38762911 PMC: 11110710. DOI: 10.1080/19336950.2024.2355150.


Untangling Macropore Formation and Current Facilitation in P2X7.

Cevoli F, Arnould B, Peralta F, Grutter T Int J Mol Sci. 2023; 24(13).

PMID: 37446075 PMC: 10341454. DOI: 10.3390/ijms241310896.


Purinergic signaling: Diverse effects and therapeutic potential in cancer.

Kaur J, Dora S Front Oncol. 2023; 13:1058371.

PMID: 36741002 PMC: 9889871. DOI: 10.3389/fonc.2023.1058371.


Improved ANAP incorporation and VCF analysis reveal details of P2X7 current facilitation and a limited conformational interplay between ATP binding and the intracellular ballast domain.

Durner A, Durner E, Nicke A Elife. 2023; 12.

PMID: 36598131 PMC: 9859053. DOI: 10.7554/eLife.82479.